First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

A new antipsychotic drug to treat symptoms of psychosis associated with Parkinson’s disease like hallucinations and delusions has become the first to be approved by the FDA.

The drug, called Nuplazid (pimavanserin), is the first of its kind on the market for use by people living with Parkinson’s in the US. It works only on the serotonin system, meaning – unlike previous antipsychotic medication – it doesn’t worsen motor symptoms.

It is estimated that around half the people with the condition may at some point experience hallucinations (seeing things that aren’t there) or delusions (holding false, paranoid, beliefs), also referred to as psychosis.

Dr Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said: “Nuplazid represents an important treatment for people with Parkinson’s.”

Nuplazid is developed by Acadia Pharmaceuticals and will be available from June 2016 at the estimated annual cost of US$23,400.

Last Month

Next Month

Go Back

Share this story

Comments

Global update

“People are not getting the same care”: health disparities and Parkinson’s

Three takeaways from the Davis Phinney Foundation webinar

Broccoli and salmon crustless quiche

This protein-rich quiche recipe is perfect served hot or cold

Sir Roger Bannister, runner, neurologist and person with Parkinson’s, has died

A tribute to Sir Roger Bannister’s service to sport and neurology

New insights on immune cell process and Parkinson’s disease

Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…

Could analysing skin oil help diagnose Parkinson’s disease?

Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.

‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia

Dyskinesia is often caused by extended use of the common Parkinson’s medication levodopa – and can be debilitating for those with the condition. Now, researchers in the US may have found a way to suppress these involuntary movements through a protein called ‘sonic hedgehog’. To conduct their study, the team administered levodopa and sonic hedgehog agonists to rodent and non-human primate models of the condition. The results revealed that dopamine neurons use the protein to communicate with other neurons thought to play a role in levodopa-induced dyskinesia. Increased signalling of sonic hedgehog pathways was found to reduce this dyskinesia – providing “novel insight” into its formation and a “potential therapeutic solution”. “What we find,” wrote corresponding study author Professor Andreas Kottmann, “is that in several animal models, by replacing … dopamine together with agonists that mimic the effects of sonic hedgehog, these dyskinesias can be very much suppressed.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

“People are not getting the same care”: health disparities and Parkinson’s

Recipes & Nutrition

Broccoli and salmon crustless quiche

Perspectives

Sir Roger Bannister, runner, neurologist and person with Parkinson’s, has died

New insights on immune cell process and Parkinson’s disease

Could analysing skin oil help diagnose Parkinson’s disease?

‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia

{title}

Subscribe

First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Global update

“People are not getting the same care”: health disparities and Parkinson’s

Recipes & Nutrition

Broccoli and salmon crustless quiche

Perspectives

Sir Roger Bannister, runner, neurologist and person with Parkinson’s, has died

New insights on immune cell process and Parkinson’s disease

Could analysing skin oil help diagnose Parkinson’s disease?

‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia

{title}

Subscribe

Sign in